Phase 2 Trial of a Neurokinin-1 Receptor Antagonist for the Treatment of Chronic Itch in Epidermolysis Bullosa Patients: A Randomized Clinical Trial

Chronic pruritus causes major morbidity in epidermolysis bullosa (EB). The substance P-neurokinin 1 receptor (SP-NK1) pathway is a promising target for treating EB-related pruritus.

Source: Journal of the American Academy of Dermatology - September 17, 2019 Category: Dermatology Authors: Albert S. Chiou, Sara Choi, Melissa Barriga, Yana Dutt-Singkh, Daniel C. Solis, Jaron Nazaroff, Irene Bailey-Healy, Shufeng Li, Kim Shu, Mark Joing, Paul Kwon, Jean Y. Tang Source Type: research